- Report
- April 2025
- 175 Pages
Global
From €3969EUR$4,490USD£3,434GBP
- Report
- March 2025
- 175 Pages
Global
From €3969EUR$4,490USD£3,434GBP
- Drug Pipelines
- April 2025
- 280 Pages
Global
From €2652EUR$3,000USD£2,294GBP
- Drug Pipelines
- April 2025
- 120 Pages
Global
From €1768EUR$2,000USD£1,529GBP
- Report
- September 2025
- 279 Pages
Global
From €5171EUR$5,850USD£4,474GBP
- Report
- September 2025
- 363 Pages
Global
From €5171EUR$5,850USD£4,474GBP
- Report
- May 2025
- 100 Pages
Global
From €4331EUR$4,900USD£3,747GBP
- Clinical Trials
- April 2025
- 550 Pages
Global
From €4419EUR$5,000USD£3,824GBP
- Report
- June 2025
- 400 Pages
Global
From €4374EUR$4,949USD£3,785GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2465EUR$2,789USD£2,133GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2465EUR$2,789USD£2,133GBP
- Report
- September 2023
- 100 Pages
Global
From €5259EUR$5,950USD£4,550GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2873EUR$3,250USD£2,485GBP
- Report
- February 2022
- 308 Pages
Global
From €8397EUR$9,500USD£7,265GBP
- Report
- May 2024
- 140 Pages
Global
From €5744EUR$6,499USD£4,970GBP
- Report
- May 2024
- 128 Pages
Global
From €5744EUR$6,499USD£4,970GBP
- Report
- May 2024
- 135 Pages
Global
From €5744EUR$6,499USD£4,970GBP
- Report
- May 2024
- 138 Pages
Global
From €5744EUR$6,499USD£4,970GBP
- Report
- September 2022
- 185 Pages
Asia Pacific
From €3049EUR$3,450USD£2,638GBP
- Report
- September 2022
- 162 Pages
Africa, Middle East
From €3049EUR$3,450USD£2,638GBP

Cetuximab is a monoclonal antibody used in the treatment of lung cancer. It is used in combination with chemotherapy to treat non-small cell lung cancer (NSCLC). Cetuximab works by targeting the epidermal growth factor receptor (EGFR), which is found on the surface of some cancer cells. This helps to slow down or stop the growth of cancer cells. Cetuximab is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC in combination with chemotherapy. It is also approved for the treatment of metastatic colorectal cancer.
Cetuximab is available in both intravenous and subcutaneous formulations. It is typically administered in combination with chemotherapy drugs such as cisplatin, carboplatin, and paclitaxel. Common side effects of cetuximab include skin rash, fatigue, nausea, and diarrhea.
Some companies in the Cetuximab market include Merck & Co., Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and F. Hoffmann-La Roche Ltd. Show Less Read more